© 2000 by Oxford University Press
Journal of the National Cancer Institute, Vol. 92, No. 19, 1601-1607,
October 4, 2000
© 2000 Oxford University Press
REPORT |
A Model to Select Chemotherapy Regimens for Phase III Trials for Extensive-Stage Small-Cell Lung Cancer
Affiliations of authors: T. T. Chen, R. Simon (Biometric Research Branch, Division of Cancer Treatment and Diagnosis), E. Feigal (Division of Cancer Treatment and Diagnosis), B. E. Johnson (Medicine Branch, Division of Clinical Sciences), National Cancer Institute, Bethesda, MD; J. P. Chute, Division of Hematology/Oncology and the Naval Medical Research Center, National Naval Medical Center, Bethesda.
Correspondence to present address: T. Timothy Chen, Ph.D., Biostatistics Section, University of Maryland Greenebaum Cancer Center, 22 South Greene St., Baltimore, MD 21201 (e-mail: tchen001{at}umaryland.edu).
Background: Many more phase II studies have favorable outcomes than the subsequent phase III trials. We used historical data from phase II and phase III studies for patients with extensive-stage small-cell lung cancer (SCLC) to generate a statistical model to provide assistance in selecting chemotherapy regimens from phase II studies for subsequent use in phase III randomized studies. Methods: Information from 21 phase III trials for patients with extensive-stage SCLC initiated during the period from 1972 through 1990 was reviewed to identify those that were preceded by phase II studies of the same regimen. We used data from all the trial pairs to develop a statistical model in which the number of patients, the median survival of patients, and the number of deaths observed in the phase II trial are used to estimate the statistical power of the subsequent phase III trial. All statistical tests were two-sided. Results: Nine phase II studies were identified that preceded phase III trials of the same regimen. The regimens from two phase II studies with the greatest expected power in the phase III trial (0.62 and 0.58) both demonstrated significantly prolonged survival when compared with standard treatment in subsequent phase III trials (P<.001 and P = .002, respectively). The regimens from six of the other phase II studies, for which the median power expected in the phase III trial was 0.28 (range, 0.19–0.52), showed no difference when compared with standard treatment in a phase III trial. Conclusions: Phase II studies for particular regimens that have an expected power of greater than 0.55 provide a reasonable basis for proceeding with a phase III trial.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  R. A. Miksad, M. Gonen, T. J. Lynch, and T. G. Roberts Jr Interpreting Trial Results in Light of Conflicting Evidence: A Bayesian Analysis of Adjuvant Chemotherapy for Non-Small-Cell Lung Cancer J. Clin. Oncol., May 1, 2009; 27(13): 2245 - 2252. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. J. Shih Go/No-Go Decisions from Phase II to Phase III Clinical Trials Am. Assoc. Cancer Res. Educ. Book, April 12, 2008; 2008(1): 217 - 221. [Full Text] [PDF]
|
|
|
|
|
|
M. I. Zia, L. L. Siu, G. R. Pond, and E. X. Chen Comparison of Outcomes of Phase II Studies and Subsequent Randomized Control Studies Using Identical Chemotherapeutic Regimens J. Clin. Oncol., October 1, 2005; 23(28): 6982 - 6991. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. F. Tannock, R. de Wit, W. R. Berry, J. Horti, A. Pluzanska, K. N. Chi, S. Oudard, C. Theodore, N. D. James, I. Turesson, et al. Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer N. Engl. J. Med., October 7, 2004; 351(15): 1502 - 1512. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. L. Schilsky Hurry Up and Wait: Is Accelerated Approval of New Cancer Drugs in the Best Interests of Cancer Patients? J. Clin. Oncol., October 15, 2003; 21(20): 3718 - 3720. [Full Text] [PDF]
|
|
|
|
|
|
T. G. Roberts Jr, T. J. Lynch Jr, and B. A. Chabner The Phase III Trial in the Era of Targeted Therapy: Unraveling the "Go or No Go" Decision J. Clin. Oncol., October 1, 2003; 21(19): 3683 - 3695. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Freidlin, O. S. Breathnach, and B. E. Johnson A Model to Select Regimens for Phase III Trials for Patients with Advanced-Stage Non-Small Cell Lung Cancer Clin. Cancer Res., March 1, 2003; 9(3): 917 - 922. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. S. Breathnach, B. Freidlin, B. Conley, M. R. Green, D. H. Johnson, D. R. Gandara, M. O'Connell, F. A. Shepherd, and B. E. Johnson Twenty-Two Years of Phase III Trials for Patients With Advanced Non-Small-Cell Lung Cancer: Sobering Results J. Clin. Oncol., March 15, 2001; 19(6): 1734 - 1742. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Buyse, P. Thirion, R. W. Carlson, T. Burzykowski, G. Molenberghs, and P. Piedbois Re: A Model to Select Chemotherapy Regimens for Phase III Trials for Extensive-Stage Small-Cell Lung Cancer J Natl Cancer Inst, March 7, 2001; 93(5): 399 - 400. [Full Text] [PDF]
|
|
|
|
|
|
T. T. Chen, J. P. Chute, E. Feigal, B. E. Johnson, and R. Simon RESPONSE: Re: A Model to Select Chemotherapy Regimens for Phase III Trials for Extensive-Stage Small-Cell Lung Cancer J Natl Cancer Inst, March 7, 2001; 93(5): 400 - 401. [Full Text] [PDF]
|
|
|
|
|
|
R. Pazdur Response Rates, Survival, and Chemotherapy Trials J Natl Cancer Inst, October 4, 2000; 92(19): 1552 - 1553. [Full Text] [PDF]
|
|